Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mohammed Elmourtada Abdulgayoom։ Caplacizumab-Enabled Treatment of iTTP Without Plasma Exchange
Aug 7, 2026, 15:42

Mohammed Elmourtada Abdulgayoom։ Caplacizumab-Enabled Treatment of iTTP Without Plasma Exchange

Mohammed Elmourtada Abdulgayoom, Clinical Hematology Specialist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical and Applied Thrombosis/Hemostasis, adding։

”I’m pleased to share our new publication in Clinical and Applied Thrombosis/Hemostasis:

‘Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations.’

In this narrative review, we examine the evolving evidence for caplacizumab-based, plasma exchange–free management of immune-mediated TTP.

This approach may be feasible in carefully selected, clinically stable patients when combined with adequate immunosuppression, close ADAMTS13 monitoring, assessment of the early platelet response, and immediate access to rescue plasma exchange when required.

Many thanks to my co-authors Nabeel Qasem, Yousef Al-Asa’d, Awni Alshurafa, and Mohamed Yassin for their valuable collaboration and contributions.”

Title: Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations

Authors: Nabeel Qasem, Yousef Al-Asa’d, Mohammed Abdulgayoom, Awni Alshurafa, Mohamed Yassin

Mohammed Elmourtada Abdulgayoom։ Caplacizumab-Enabled Treatment of iTTP Without Plasma Exchange

Stay updated on all scientific advances with Hemostasis Today.